



22nd August 2014

2014 SHARE PURCHASE PLAN – CLOSURES OVERSUBSCRIBED

SomnoMed Limited (SOM: ASX) is pleased to announce the successful completion of its 2014 Share Purchase Plan (“SPP”), which closed on Friday 15th August 2014.

There was overwhelming demand under the SPP, which was sent to all eligible shareholders who were registered on 24th July 2014. The Company received in excess of 500 valid applications, representing approximately \$6.1 million in subscriptions, well in excess of the maximum of \$1.5 million available under this offer. Due to this overwhelming demand there will be a significant scale back on the participant amount per shareholder, in accordance with the terms of the SPP.

“We are very grateful for the overwhelming support and interest received from shareholders. Applications for the subscription of shares received were four times higher than the number of shares we could justify to issue. As a result, we have raised \$7 million in additional capital from the recent placement and SPP (of which \$405,000 will be subscribed by Director related entities, subject to shareholder approval), which will allow us to continue with our process to build a successful, fast growing global medical device company. We are very appreciative of this tremendous sign of confidence in SomnoMed’s future and we are sorry to have caused disappointment to shareholders and stock brokers who were prepared to take up a much higher number of shares than those being issued to them,” said Dr Peter Neustadt, Executive Chairman, SomnoMed Limited.

A total of 1 million shares has been allotted today for shares issued under the SPP and refunds resulting from the validation process and scale-back will be dispatched to shareholders in the week commencing 25th August 2014.

The Board determined that no shareholders who participated in the recent placement, raising in excess of \$5 million, would be allocated shares under the SPP. In scaling applications the Board considered the shareholding of the relevant shareholder at the record date, with shareholders receiving a proportionally greater percentage of their application depending upon the shareholder’s holding at the record date.

For enquiries regarding the SPP please contact our share registry Boardroom Pty Limited on (02)9290 9600.

Contact: Dr. Peter Neustadt – Executive Chairman and CEO, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592 - mobile

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent[®] is the most comfortable and effective design and treatment solution for over 175,000 patients in 24 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>